Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Remitly Global Inc (RELY) Price & Performance

DexCom, Inc.Trade
Remitly Global IncTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Remitly Global Inc — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.08B), while Remitly Global Inc trades at $23.73 (market cap $4.87B). The key difference: DexCom, Inc. is far larger — about 6.8× Remitly Global Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Remitly Global Inc nearer its low. Which is the better fit depends on your goals.

DXCMRELY
Market Cap
$33.08B$4.87B
Sector
HealthTechnology
52-Week High
$89.53$25.93
52-Week Low
$54.84$12.20
Enterprise Value
$32.53B$4.23B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.

Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.

Remitly Global Inc

RELY stock trades at $24.42, down 5.82% over 24 hours, but maintains strong bullish technical signals with support at $24 and resistance at $26. The company demonstrates impressive fundamental momentum with Q2 2026 EPS of $0.93 beating expectations by 650% and revenue growth accelerating to 20% year-over-year. Recent initiatives include the Global Card launch and UAE licensing expansion, positioning for continued market share gains in the $800 billion remittance market.

With 92% analyst buy ratings and a $31 consensus price target implying 27% upside, RELY presents compelling growth potential. Key risks include execution challenges in new product launches and competitive pressure in digital payments. The stock's valuation at 17.56x P/E appears reasonable given 32.25% ROE and projected 16.85% net margins for 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Remitly Global Inc

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

Read more on RELY